ArticleACS omega2026
A Dual-Activated Catalytic Hairpin Assembly Signal Amplification Nanoplatform for High-Sensitivity Detection of Dual-Target MicroRNAs.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of hepatocellular carcinoma is crucial for improving patient prognosis, and microRNA (miRNA) detection via liquid biopsy is important. However, the low abundance, high homology, and complex background interference of miRNAs in biological samples pose serious challenges to the sensitivity and specificity of their detction techniques. This study developed a catalytic hairpin assembly (CHA) signal amplification platform with dual activation of near-infrared light (NIR) and glutathione (GSH), combined with the low background fluorescence properties of upconversion nanoparticles (UCNPs) for the accurate and specific quantification of both miRNA-21 and miRNA-221. Under optimized conditions, the limits of detection for miRNA-21 and miRNA-221 were 0.266 and 0.113 nM, respectively. The recovery rates in the serum spiked experiments ranged from 98.0 to 107.1%, with a low relative standard deviation (<4.84%), suggesting that the method has good accuracy and reliability. The constructed NIR/GSH dual-activation CHA-sensing platform not only offers a novel approach for the determination of low-abundance miRNAs in complex biological samples but also establishes a feasible foundation for the development of advanced theranostic nanoplatforms for early screening and subtyping diagnosis of hepatocellular carcinoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.